Hubei Biocause Heilen Pharmaceutical Co. Ltd. Total Assets

Latest as of March 2026: CN¥2.40 Billion CNY ≈ $351.21 Million USD

Hubei Biocause Heilen Pharmaceutical Co. Ltd. total assets. Based on the latest financial reports, Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) holds total assets worth CN¥2.40 Billion CNY (≈ $351.21 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Hubei Biocause Heilen Pharmaceutical Co. market capitalisation for the company's overall valuation and market capitalisation.

Total Assets of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)

Total assets of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025. This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total assets have evolved over time, based on quarterly financial data. See Hubei Biocause Heilen Pharmaceutical Co. share price for real-time trading data and today's change.

Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Asset Composition Analysis

Hubei Biocause Heilen Pharmaceutical Co. Ltd. Total Assets Breakdown (December 2025)

Hubei Biocause Heilen Pharmaceutical Co. Ltd. total assets breakdown as of December 2025. Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total assets of CN¥2.40 Billion consist of 74.6% current assets and 25.4% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	18.6%
Accounts Receivable	CN¥63.47 Million	2.6%
Inventory	CN¥122.68 Million	5.1%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥70.44 Million	2.9%
Goodwill	CN¥0.00	0.0%

Asset Composition Trend (2017–2025)

This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Hubei Biocause Heilen Pharmaceutical Co. (301211) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s current assets represent 74.6% of total assets in 2025, an increase from 65.6% in 2017.
Cash Position: Cash and equivalents constituted 18.6% of total assets in 2025, up from 9.1% in 2017.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 8.0% in 2017.
Asset Diversification: The largest asset category is inventory at 5.1% of total assets.

Hubei Biocause Heilen Pharmaceutical Co. Ltd. Competitors by Total Assets

Key competitors of Hubei Biocause Heilen Pharmaceutical Co. Ltd. based on total assets are shown below.

Company	Country	Total Assets
Jiangsu Hengrui Medicine Co Ltd SHG:600276	China	CN¥68.33 Billion
Sandoz Group AG SW:SDZ	Switzerland	CHF22.86 Billion
H Lundbeck A/S CO:HLUN-B	Denmark	Dkr54.01 Billion
Changchun High & New Technology Industries Group Inc SHE:000661	China	CN¥30.77 Billion
Hubei Jumpcan Pharmaceutical Co Ltd SHG:600566	China	CN¥17.01 Billion
Kangmei Pharmaceutical Co Ltd SHG:600518	China	CN¥13.68 Billion
Viyash Scientific Limited NSE:SEQUENT	India	Rs17.26 Billion
Anhui Fengyuan Pharmaceutical Co Ltd SHE:000153	China	CN¥5.11 Billion

Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	17.18	13.67	7.45
Quick Ratio	15.97	12.69	6.20
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥1.69 Billion	CN¥1.72 Billion	CN¥572.14 Million

Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Advanced Valuation Insights

This section examines the relationship between Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	2.13
Latest Market Cap to Assets Ratio	0.28
Asset Growth Rate (YoY)	-3.5%
Total Assets	CN¥2.40 Billion
Market Capitalization	$669.13 Million USD

Valuation Analysis

Below Book Valuation: The market values Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s assets decreased by 3.5% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)

The table below shows the annual total assets of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025.

Year	Total Assets	Change
2025-12-31	CN¥2.40 Billion ≈ $351.47 Million	-3.49%
2024-12-31	CN¥2.49 Billion ≈ $364.17 Million	-2.27%
2023-12-31	CN¥2.55 Billion ≈ $372.64 Million	+1.96%
2022-12-31	CN¥2.50 Billion ≈ $365.50 Million	+7.18%
2021-12-31	CN¥2.33 Billion ≈ $341.00 Million	+190.11%
2020-12-31	CN¥803.25 Million ≈ $117.54 Million	+7.74%
2019-12-31	CN¥745.56 Million ≈ $109.10 Million	+16.45%
2018-12-31	CN¥640.24 Million ≈ $93.69 Million	+19.69%
2017-12-31	CN¥534.90 Million ≈ $78.27 Million	--

About Hubei Biocause Heilen Pharmaceutical Co. Ltd.

SHE:301211 China Drug Manufacturers - Specialty & Generic

Market Cap

$669.13 Million

CN¥4.57 Billion CNY

Market Cap Rank

#10489 Global

#2784 in China

Share Price

CN¥10.95

Change (1 day)

+4.19%

52-Week Range

CN¥9.28 - CN¥16.03

All Time High

CN¥44.40